It is our hope that this review will provide more extensive evidence on the tremendous
patient safety benefits that checklists offer and will lead to the consistent adoption of their use in surgery.»
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror
patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured
patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the
benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and
patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs;
safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Palladio Group, together with E Ink, was granted a Silver Award in the 28th DuPont Awards for Packaging Innovation for their
patient - forward packaging design for PhutureMed ™ — an excellent example of packaging innovation that
benefits the greater good by advancing
patient safety.
Administrative requirements that ensure the
safety and ethical foundation of clinical research
benefit patients, investigators, and society, but experts have debated the effectiveness of some requisites.
In the past few years alone, researchers have had to backtrack on the health
benefits of low - fat, high - fiber diets and the value and
safety of hormone replacement therapy as well as the arthritis drug Vioxx, which was pulled from the market after being found to cause heart attacks and strokes in high - risk
patients.
The opportunity for low - income
patients to
benefit from hearing rehabilitation at minimal personal cost can represent an effective extension of
safety net services,» the authors write.
Their
patients benefit by being closely monitored to assess the efficacy and
safety of novel medications that are intended to treat their disease.
The drug was originally approved in 2000 as a stand - alone treatment for older
patients with CD33 - positive AML who had had a relapse, but was eventually withdrawn after subsequent trials failed to confirm a clinical
benefit and raised
safety concerns.
It will be important to follow
patients for many years to confirm the therapy's long - lasting
safety and health
benefits.
We are examining ways to improve and support the responsible sharing of data by NHS clinical genetics / genomics services for
patient benefit,
patient safety and service quality
Whilst
patient benefit should be the focus of the Genomic Medicine Service, income generated from NHS data can be reinvested in the NHS to
benefit future
patients; Genomics England should continue to provide industrial and academic access to these data to facilitate the growth of the UK genomics industry and the development of new treatments, while ensuring consent and data
safety safeguards.
Their roll - out into translational practice will not be free of complexity, however, as culture and values differ in terms of what defines
benefit and risk, who will
benefit and who is at risk, what methods must be in place to assure the maximum
safety, comfort, and protection of subjects and
patients, and educational and policy needs.
We believe CMB305's potential
benefit to
patients will be the combination of a favorable
safety profile with improved survival, and as such are focused on overall survival and
safety as the primary endpoints of these studies.
And «because the
safety and effectiveness of ayahuasca has yet to be determined, it should only be used in the context of careful research studies, designed to protect the
safety of
patients, while generating data that could inform the overall balance of risks and
benefits associated with this drug,» he said
I like everything about it because it equals out to
benefit the
patients overall health condition,
safety,
patient education, concerns, care and needs.
At the Medical Sales College, we offer the best - trained professional representatives for the
benefit of the employer, hospital and
patient safety.
Cultural
safety promotes an understanding of the culture of health and asks nurses and midwives to be learn to be more responsive to the needs of the
patient generally, and this only
benefits patients.